Multiple myeloma clinical presentation

In terms of clinical activity, promising results from a Phase I trial investigating KOS953 in patients with multiple myeloma were presented at the American Society of Hematology meeting in 2005. Among the 22 patients who received KOS953, one patient had a measurable response while two showed partial responses. 

Clinically, amyloidosis is classified (omitting some rare forms) into five main groups (1) primary amyloidosis, (2) amyloidosis associated with multiple myeloma, (3) secondary amyloidosis associated with inflammatory or infectious diseases, (4) a form associated with aging, and (5) familial amyloidosis. Increased knowledge of the chemical structure of the deposits has led to a revised classification that takes into consideration the type of amyloid protein present. Tins classification is used in Table 20-14. 

---